The Cancer Letter

Inside information on cancer research and drug development

Clinical

Indefinite course of osimertinib dramatically improves PFS in stage 3 EGFR-mutated NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Treatment with an indefinite course of osimertinib dramatically improves progression-free survival for patients with stage 3 non-small cell cancer, according to the results of the LAURA trial. The median PFS was 39.1 months in the osimertinib group, compared to 5.6 months with the placebo group.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Jacquelyn Cobb
Associate Editor
McKenzie Prillaman
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Tiragolumab + atezolizumab for metastatic nSq NSCLC did not meet primary endpoints in phase II/III trial

Genentech, a member of the Roche Group, announced that the phase II/III SKYSCRAPER-06 study evaluating tiragolumab plus Tecentriq (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial treatment for people with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer, did not meet its primary endpoints of progression-free survival at its primary analysis with a hazard ratio of 1.27 [95% CI: 1.02,1.57] and overall survival at its first interim analysis with a HR of 1.33 [95% CI: 1.02, 1.73], which was immature. 
Cancer History ProjectGuest Editorial

At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.
By Katerina A. Politi and Roy S. Herbst
Byline
Jacquelyn Cobb
Associate Editor
McKenzie Prillaman
Reporter
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account